Iovance Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of tumor-infiltrating lymphocyte (TIL) therapies for patients with solid tumors. The company’s lead candidate, lifileucel, is a one-time, autologous TIL therapy engineered to enhance the body’s immune response against malignant cells. Iovance’s pipeline also includes additional TIL-based programs targeting indications such as cervical, head and neck, and non–small cell lung cancers.
Iovance designs its cell therapies using proprietary manufacturing processes that collect and expand patients’ own tumor-reactive T cells before reintroducing them to the body. The company operates a Good Manufacturing Practice (GMP) facility in Philadelphia and collaborates with a network of academic centers and contract manufacturers to support large-scale production. Clinical trials for lifileucel and other TIL candidates are underway in the United States and Europe, with regulatory filings planned in multiple jurisdictions.
Founded in 2007 as Genesis Biopharma and later merged with Lion Biotechnologies, the company rebranded as Iovance Biotherapeutics in 2021 to reflect its evolving pipeline and global ambitions. Headquartered in San Carlos, California, Iovance has established research alliances and clinical partnerships across North America, Europe and Australia. The company’s R&D activities are bolstered by collaborations with leading cancer centers and academic institutions specializing in immuno-oncology.
Iovance is led by a management team with deep expertise in cell therapy development, clinical oncology and regulatory affairs. The company’s senior leadership includes professionals who have guided multiple biologic product approvals and built substantial manufacturing infrastructures. An experienced board of directors and an advisory panel of immunotherapy pioneers support Iovance’s strategic direction as it advances toward potential commercial launches.
AI Generated. May Contain Errors.
